Eyeworld

Step by step: Clinical and practical implementation of laser-assisted cataract surgery Supplement to EyeWorld October 2015 continued on page 2 post-activity test with a score of 75% or higher to earn credit. Alternatively, the post-test form included in this supplement may be faxed to the number indicated for credit to be awarded, and a certificate will be mailed within 2 weeks. When viewing online or downloading the material, standard Internet access is required. Adobe Acrobat Reader is needed to view the materials. CME credit is valid through April 30, 2016. CME credit will not be awarded after that date. Notice of Off-Label Use Presentations This activity may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Adminis- tration (FDA) or have been approved by the FDA for specific uses only. ADA/Special Accommodations ASCRS and EyeWorld fully comply with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Any participant in this educational program who requires special accommodations or services should contact Laura Johnson at ljohnson@ascrs.org or 703-591- 2220. Financial Interest Disclosures David M. Dillman, MD, has received a retainer, ad hoc fees or other consulting income from Alcon Laboratories Inc. and Sightpath Medical. Eric D. Donnenfeld, MD, has received a retainer, ad hoc fees or other consulting income from: Abbott Medical Optics Inc., AcuFocus Inc., Alcon Labora- tories Inc., Allergan, AqueSys Inc., Bausch + Lomb, CRST, Elenza, Glaukos Corporation, Icon Biosciences, Kala Pharmaceuticals, Katena, Mati Pharmaceuticals, Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American Society of Cataract & Refractive Surgery (ASCRS) and EyeWorld. ASCRS is accredited by the ACCME to provide continuing medical education for physicians. Educational Objectives Ophthalmologists who participate in this activity will: • Analyze the quantity and quality of the available literature and studies demonstrating the key safety and efficacy improvements of LACS over conventional cataract surgery; • Describe different reimbursement and practice flow models in a variety of practice settings that permit the viable integration of LACS into a refractive cataract practice; and • Assess the impact of improving the manage- ment of residual corneal error, pre-cleaved lenticular material and the ocular surface in LACS and premium IOL patients. Designation Statement The American Society of Cataract & Refractive Sur- gery designates this enduring materials educational activity for a maximum of 1.0 AMA PRA Category 1 Credits. ™ Physicians should claim only credit commensurate with the extent of their participation in the activity. Claiming Credit To claim credit, participants must visit bit.ly/1No2lzh to review content and download the post-activity test and credit claim. All participants must pass the Merck & Co. Inc., Mimetogen Pharmaceuticals USA Inc., NovaBay, OcuHub, Odyssey Medical Inc., Omer- os Corporation, Pfizer Inc., PRN, RPS, Shire Pharma- ceuticals, Strathspey Crown, TearLab, and TCL. Richard L. Lindstrom, MD, has received a retainer, ad hoc fees or other consulting income from, re- ceived royalties from, and has an investment interest in: AcuFocus Inc., Bausch + Lomb, and Quest. He has received a retainer, ad hoc fees or other con- sulting income from, is a member of the speakers bureaus of, and has an investment interest in: Abbott Medical Optics Inc., BioSyntrx, Calhoun Vision Inc., Clarity Ophthalmics, Clear Sight, CoDa Therapeutics, EBV Partners, Encore, Evision Photography, Eyemag- inations Inc., Glaukos Corporation, High Performance Optics, Improve Your Vision, LENSAR Inc., LenSx, Lifeguard Health, Minnesota Eye Consultants, Nu- Lens, Ocular Optics, Ocular Therapeutix Inc., Omega Eye Health, Pixel Optics, Refractec, Schroder Life Science, Sightpath Medical, Surgijet/Visijet, TearLab, TLC, Tracey Technologies, Transcend Medical Inc., TrueVision, Vision Solutions Technology, and 3D Vision Systems. He has received a retainer, ad hoc fees or other consulting income from: Advanced Refractive Technologies, Alcon Laboratories Inc., Foresight Venture Fund #3, ForSight Labs, Hoya, ISTA, Lumineyes Inc., OSN, Omeros Corporation, Seros Medical LLC, Strathspey Crown, Versant, and Viradex. Dr. Lindstrom has investment interests in: Confluence Acquisition Partners, Curveright LLC, CXL Ophthalmics LLC, Evision Medical Laser, FzioMed, Healthcare Transaction Services, Heaven Fund, Nisco, One Focus Ventures, OnPoint, Rainwater Healthcare, Sarbox NP, SARcode Corp., Solbeam, TriPrima, and WaveTec Vision. Kerry D. Solomon, MD, has received a retainer, ad hoc fees or other consulting income from, is a member of the speakers bureaus of, and has an investment interest in: AqueSys Inc., Glaukos Corporation, and WaveTec Vision. He has an invest- ment interest in Mati Pharmaceuticals and Versant Ventures. Dr. Solomon has received research funding from WaveTec Vision. He has received a retainer, ad hoc fees or other consulting income, travel expense reimbursement, and research funding from Alcon Laboratories, Inc. William B. Trattler, MD, has received a retainer, ad hoc fees or other consulting income from: Abbott Medical Optics Inc., Alcon Laboratories Inc., Allergan, Bausch + Lomb, CXL Ophthalmics LLC, Imprimis Pharmaceuticals, and Omeros Corporation. He is a member of the speakers bureaus of: Abbott Medial Optics Inc., Allergan, Bausch + Lomb, and Oculus. Dr. Trattler has received research funding from Alcon Laboratories Inc. and Refocus Group Inc. He has received travel expense reimbursement from Alcon Laboratories Inc. Robert J. Weinstock, MD, has received a retainer, ad hoc fees or other consulting income and travel expense reimbursement from: Bausch + Lomb and LENSAR Inc. He has received a retainer, ad hoc fees or other consulting income from Alcon Laborato- ries Inc. and STAAR Surgical. Dr. Weinstock has an investment interest in Drs Allergy Formula and TrueVision. Staff members: Laura Johnson and Erin Schallhorn have no ophthalmic-related financial interests. fragmentation, and 40.7% do not believe it improves arcuate incisions (Figure 2). provide a significant clinical bene- fit compared with conventional cataract surgery, 42.2% believe it does not provide improvements in the capsulorhexis, 47.9% believe it does not improve lens D espite advances in femtosecond laser technology, overall only 4.8% (5.8% U.S.; 3.6% non-U.S.) of ASCRS members' patients are receiving femtosecond laser-assisted cata- ract surgery (LACS), as reported in the 2014 ASCRS Clinical Survey (Figure 1). This survey, focusing on the most compelling and controver- sial issues ASCRS members face, accumulated data points from 137 questions on key clinical opinions and practice patterns from more than 1,500 unique respondents. The survey included 11 specialty sections. Survey responses When respondents were asked in which clinical areas LACS may Recommendations to help cataract surgeons launch these technologies in their practices by Richard L. Lindstrom, MD Implementing advanced cataract technologies Supported by unrestricted educational grants from Alcon Laboratories, Bausch + Lomb, LENSAR, and Sightpath Medical Richard L. Lindstrom, MD " Although large, high-volume cataract practices may be able to provide LACS on their own, a shared access model may provide options for many surgeons. " –Richard L. Lindstrom, MD

• Cover